Supplementary Table from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer

Supplementary Table from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer

Supplementary Table from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer

Kaydedildi:

Detaylı Bibliyografya
Yazar:	Martin Sjöström (14845882) (author)
Diğer Yazarlar:	Shuang G. Zhao (12227671) (author), Samuel Levy (14960811) (author), Meng Zhang (14960814) (author), Yuhong Ning (279537) (author), Raunak Shrestha (14949693) (author), Arian Lundberg (14960817) (author), Cameron Herberts (14960820) (author), Adam Foye (14960823) (author), Rahul Aggarwal (14960826) (author), Junjie T. Hua (14960829) (author), Haolong Li (1532230) (author), Anna Bergamaschi (14960832) (author), Corinne Maurice-Dror (14960835) (author), Ashutosh Maheshwari (14960838) (author), Sujun Chen (3553841) (author), Sarah W.S. Ng (14960841) (author), Wenbin Ye (14960844) (author), Jessica Petricca (14960847) (author), Michael Fraser (522709) (author), Lisa Chesner (14960850) (author), Marc D. Perry (14960853) (author), Thaidy Moreno-Rodriguez (14960856) (author), William S. Chen (14960859) (author), Joshi J. Alumkal (14950518) (author), Jonathan Chou (14957015) (author), Alicia K. Morgans (5600567) (author), Tomasz M. Beer (14960862) (author), George V. Thomas (13187926) (author), Martin Gleave (146446) (author), Paul Lloyd (14960865) (author), Tierney Phillips (4664332) (author), Erin McCarthy (14960868) (author), Michael C. Haffner (14960871) (author), Amina Zoubeidi (14960874) (author), Matti Annala (219688) (author), Robert E. Reiter (14960877) (author), Matthew B. Rettig (14960880) (author), Owen N. Witte (14960883) (author), Lawrence Fong (14960886) (author), Rohit Bose (14960889) (author), Franklin W. Huang (10726678) (author), Jianhua Luo (14960892) (author), Anders Bjartell (199682) (author), Joshua M. Lang (12227674) (author), Nupam P. Mahajan (14960895) (author), Primo N. Lara (13009812) (author), Christopher P. Evans (14960898) (author), Phuoc T. Tran (14960901) (author), Edwin M. Posadas (14960904) (author), Chuan He (178952) (author), Xiao-Long Cui (2020402) (author), Jiaoti Huang (88989) (author), Wilbert Zwart (14960907) (author), Luke A. Gilbert (5513207) (author), Christopher A. Maher (14960910) (author), Paul C. Boutros (14954698) (author), Kim N. Chi (14960913) (author), Alan Ashworth (14957030) (author), Eric J. Small (14960916) (author), Housheng H. He (14960919) (author), Alexander W. Wyatt (14960922) (author), David A. Quigley (14957012) (author), Felix Y. Feng (14845891) (author)
Baskı/Yayın Bilgisi:	2025
Konular:	Cancer Cancer Risk Factors Molecular and Cellular Biology Methods and Technology Epigenetics Epigenomics Genitourinary Cancers Prostate cancer Liquid Biopsy
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller

Figure 5 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
Yazar:: Martin Sjöström (14845882)
Baskı/Yayın Bilgisi: (2025)

Figure 1 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
Yazar:: Martin Sjöström (14845882)
Baskı/Yayın Bilgisi: (2025)

Figure 2 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
Yazar:: Martin Sjöström (14845882)
Baskı/Yayın Bilgisi: (2025)

Figure 3 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
Yazar:: Martin Sjöström (14845882)
Baskı/Yayın Bilgisi: (2025)

Figure 4 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
Yazar:: Martin Sjöström (14845882)
Baskı/Yayın Bilgisi: (2025)

Figure 6 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
Yazar:: Martin Sjöström (14845882)
Baskı/Yayın Bilgisi: (2025)

Figure 7 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
Yazar:: Martin Sjöström (14845882)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
Yazar:: Martin Sjöström (14845882)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
Yazar:: Martin Sjöström (14845882)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 1 from Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer
Yazar:: Alex Chehrazi-Raffle (17079582)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 1 from Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer
Yazar:: Alex Chehrazi-Raffle (17079582)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
Yazar:: Sofie H. Tolmeijer (15313251)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
Yazar:: Sofie H. Tolmeijer (15313251)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
Yazar:: Sofie H. Tolmeijer (15313251)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data from DNA Methylation Landscapes of Prostate Cancer Brain Metastasis Are Shaped by Early Driver Genetic Alterations
Yazar:: John Gallon (15096459)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 1. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
Yazar:: Arian Lundberg (14960817)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 2. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
Yazar:: Arian Lundberg (14960817)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 1. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
Yazar:: Arian Lundberg (14960817)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 2. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
Yazar:: Arian Lundberg (14960817)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 3. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
Yazar:: Arian Lundberg (14960817)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 1 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
Yazar:: Hong Qiu (14963144)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 2 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
Yazar:: Hong Qiu (14963144)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from G-Quadruplex Structures Are Key Modulators of Somatic Structural Variants in Cancers
Yazar:: Rongxin Zhang (15293341)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from G-Quadruplex Structures Are Key Modulators of Somatic Structural Variants in Cancers
Yazar:: Rongxin Zhang (15293341)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S5 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
Yazar:: Abdullah A. Osman (15056323)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S1 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
Yazar:: Abdullah A. Osman (15056323)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
Yazar:: Abdullah A. Osman (15056323)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
Yazar:: Abdullah A. Osman (15056323)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
Yazar:: Abdullah A. Osman (15056323)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S4 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
Yazar:: Abdullah A. Osman (15056323)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
Yazar:: Emil Christensen (15054394)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
Yazar:: Emil Christensen (15054394)
Baskı/Yayın Bilgisi: (2025)

Supplementary Tables 1 from Proteostasis Modulation in Germline Missense von Hippel Lindau Disease
Yazar:: Prashant Chittiboina (15367044)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Yazar:: Stephanie Lheureux (16797697)
Baskı/Yayın Bilgisi: (2025)

Figure 5 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
Yazar:: James R. Larkin (14936324)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data from β-Catenin–Driven Differentiation Is a Tissue-Specific Epigenetic Vulnerability in Adrenal Cancer
Yazar:: Dipika R. Mohan (15011204)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Yazar:: Whitney L. Hensing (16461978)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Yazar:: Stephanie Lheureux (16797697)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Yazar:: Stephanie Lheureux (16797697)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Yazar:: Stephanie Lheureux (16797697)
Baskı/Yayın Bilgisi: (2025)

Cannot write session to /tmp/vufind_sessions/sess_lpc1p65rem52k15ffuirpp956h